As recommended by most recent antiemetic guidelines, the optimal prophylaxis of chemotherapy-induced nausea and vomiting (CINV) requires the combinati...
641KB Sizes 1 Downloads 10 Views

Recommend Documents

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also r

Improved prophylaxis of postoperative nausea vomiting: Palonosetron a novel antiemetic.
Many anti-emetics are used in clinical practice. Palonosetron hydrochloride is one of them. It is a novel, centrally acting antiemetic, and anti-nausea agent. This drug is an antagonist of serotonin receptor subtype 3 (5-HT3). This drug has longer du

Palonosetron-Induced Ventricular Tachycardia in a Patient Receiving Cancer Chemotherapy.
Chemotherapy-induced nausea and vomiting (CINV) is one of the major and most distressing adverse effects of cancer chemotherapy. It is treated with various antiemetic regimens, of which one class of drugs is 5-hydroxytryptamine type 3 receptor antago

Analgesic effects of palonosetron in the intravenous propofol injection.
Propofol is a good induction agent, but it has the disadvantage of causing pain on intravenous injection. The incidence of propofol-induced pain is approximately 70%. Palonosetron is a novel second-generation 5-hydroxytryptamine type 3 (5-HT3) recept

Palonosetron for the treatment of chemotherapy-induced nausea and vomiting.
Chemotherapy-induced nausea and vomiting (CINV) is associated with a significant deterioration in quality of life. The emetogenicity of the chemotherapeutic agents, repeated chemotherapy cycles, and patient risk factors significantly influence CINV.

Management of acute and delayed chemotherapy-induced nausea and vomiting: role of netupitant-palonosetron combination.
The purpose of this review is to summarize and discuss the recently published data (both original studies and reviews) on the oral medication NEPA, consisting of netupitant (a neurokinin-1 receptor antagonist [NK1RA], 300 mg dose) and palonosetron (5